## Irene Canini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9068951/publications.pdf

Version: 2024-02-01

13 papers	896 citations	12 h-index	1058333 14 g-index
15	15	15	1648
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration. Clinical Cancer Research, 2007, 13, 644-653.	3.2	228
2	3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells. Scientific Reports, 2017, 7, 1093.	1.6	130
3	Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathways. Molecular and Cellular Neurosciences, 2010, 45, 234-244.	1.0	93
4	Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine, 2005, 23, 2994-3004.	1.7	88
5	HIV-1 gp120 Stimulates the Production of $\hat{l}^2$ -Chemokines in Human Peripheral Blood Monocytes Through a CD4-Independent Mechanism. Journal of Immunology, 2001, 166, 5381-5387.	0.4	72
6	LOX-1 as a natural IFN-α–mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood, 2010, 115, 1554-1563.	0.6	70
7	Endogenous CCL2 (monocyte chemotactic protein-1) modulates human immunodeficiency virus type-1 replication and affects cytoskeleton organization in human monocyte–derived macrophages. Blood, 2003, 102, 2334-2337.	0.6	55
8	Loss of Type I IFN Receptors and Impaired IFN Responsiveness During Terminal Maturation of Monocyte-Derived Human Dendritic Cells. Journal of Immunology, 2002, 169, 3038-3045.	0.4	37
9	Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus. Vaccine, 2006, 24, S56-S57.	1.7	33
10	Antitumor Effects of Epidrug/IFNα Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells. Cancer Immunology Research, 2017, 5, 604-616.	1.6	27
11	ICSBP/IRF-8 differentially regulates antigen uptake during dendritic-cell development and affects antigen presentation to CD4+ T cells. Blood, 2006, 108, 609-617.	0.6	25
12	IFN- $\hat{l}\pm$ potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. Oncotarget, 2016, 7, 26361-26373.	0.8	25
13	Impaired IFN-α-mediated signal in dendritic cells differentiates active from latent tuberculosis. PLoS ONE, 2018, 13, e0189477.	1.1	11